FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
The trial randomized 542 patients tor receive either pembrolizumab or the investigator’s choice of chemotherapy with paclitaxel, docetaxel, or vinflunine. The primary endpoints were overall survival and progression-free survival. Patients treated with pembrolizumab had superior median overall survival of 10.3 months (95% confidence interval [CI], 8.0 to 11.8) compared with 7.4 months (95% CI, 6.1 to 8.3) in the chemotherapy group (hazard ratio for death, 0.73; 95% CI, 0.59 to 0.91; P = 0.002). Pembrolizumab was also associated with fewer treatment-related adverse events (60.9% vs. 90.2%). Interestingly, there were no differences in progression free-survival between the two groups. The authors suggest that progression-free survival may not be an appropriate endpoint for future assessments of clinical benefit from immune-checkpoint inhibitors.
This key study demonstrated a clear efficacy and safety advantage for pembrolizumab over second-line chemotherapy for patients with platinum-resistant urothelial cancer. Ongoing studies will assess pembrolizumab in the first-line and adjuvant settings.
Identifying optimal biomarkers and strategies for increasing clinical benefit are expected to ultimately translate to improved clinical outcomes for urothelial carcinoma patients.
Read the Abstract
Author: Bishoy M. Faltas MD
Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF; KEYNOTE-045 Investigators. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med. 2017 Feb 17. doi: 10.1056/NEJMoa1613683. [Epub ahead of print]